Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: ______________________ Phone: __________ Fax: __________

A. PATIENT INFORMATION

First Name: | Last Name:
Address: | City: | State: | ZIP:
Home Phone: | Work Phone: | Cell Phone:
DOB: | Allergies: | Email:
Current Weight: ________ lbs or ________ kgs Height: ________ inches or ________ cms

B. INSURANCE INFORMATION

Aetna Member ID #: ______________________
Group #: ______________________
Insured: ______________________

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: ____________ Carrier Name: ____________
Insured: ______________________

Medicare: ☐ Yes ☐ No If yes, provide ID #: ____________ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: ____________

C. PRESCRIBER INFORMATION

First Name: | Last Name: | *(Check One)*: ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.
Address: | City: | State: | ZIP:
Phone: | Fax: | St Lic #: | NPI #: | DEA #: | UPIN:
Provider Email: | Office Contact Name: | Phone:
Specialty *(Check one)*: ☐ **Oncologist** ☐ **Other**: ______________________

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: ______________
Center Name: ______________________
☐ Home Infusion Center Phone: ______________
Agency Name: ______________________
Address: ______________________
☐ Administration code(s) (CPT): ______________________

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other ______________
Name: ______________________
Address: ______________________
Phone: ______________ Fax: ______________
TIN: ______________ PIN: ______________

E. PRODUCT INFORMATION

Request is for: ☐ **Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Dose:** __________ **Frequency:** __________

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: ______________ Secondary ICD Code: ______________ Other ICD Code: ______________

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

☐ Yes ☐ No Has the patient tried and failed treatment with Herzuma (trastuzumab-pkrb) and Ogivri (trastuzumab-dkst) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information?

For Initiation Requests (clinical documentation required):

What is the human epidermal growth factor receptor 2 (HER2) status? ☐ HER2 positive ☐ HER2 negative ☐ Unknown

☐ **Breast cancer**

Please select the clinical setting in which the requested medication is being used:

☐ Adjuvant therapy
→ ☐ Yes ☐ No Has the patient previously been treated with the requested drug as neoadjuvant or adjuvant therapy?
How many months has the patient received therapy with the requested medication? _____
☐ Treatment of recurrent disease
☐ Treatment of unresectable disease
☐ Treatment of advanced disease
☐ Treatment of metastatic disease

Continued on next page

Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION ***(continued)*** – Required clinical information must be completed in its entirety for all precertification requests.

☐ Neoadjuvant therapy
- ☐ Yes ☐ No Will the requested drug be used as part of a complete treatment regimen?
- ☐ Yes ☐ No Has the patient previously been treated with the requested drug as neoadjuvant or adjuvant therapy?
- How many months has the patient received therapy with the requested medication? _____

For Continuation Requests (clinical documentation required):

☐ Yes ☐ No Has the patient experienced disease progression or unacceptable toxicity while on the current regimen?

For adjuvant or neoadjuvant treatment of breast cancer, how many months of the requested medication has the patient received? _____

H. ACKNOWLEDGEMENT

Request Completed By ***(Signature Required):*** ____________________ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.